The developmental regulator SOX9 is linked to cancer progression mainly as a result of its role in the regulation of cancer stem cells (CSCs). However, its activity in the differentiated cells that constitute the heterogeneous tumor bulk has not been extensively studied. In this work, we addressed this aspect in gastric cancer, glioblastoma and pancreatic adenocarcinoma. SOX9 silencing studies revealed that SOX9 is required for cancer cell survival, proliferation and evasion of senescence in vitro and tumor growth in vivo. Gain of-SOX9 function showed that high levels of SOX9 promote tumor cell proliferation in vitro and in vivo. Mechanistically, the modulation of SOX9 changed the expression of the transcriptional repressor BMI1 in the same direction in the three types of cancer, and the expression of the tumor suppressor p21 cip in the opposite direction. In agreement with this, SOX9 expression positively correlated with BMI1 levels and inversely with p21 cip in clinical samples of the different cancers. Moreover, BMI1 re-establishment in SOX9-silenced tumor cells restored cell viability and proliferation as well as decreased p21 cip in vitro and tumor growth in vivo. These results indicate that BMI1 is a critical effector of the pro-tumoral activity of SOX9 in tumor bulk cells through the repression of p21 cip . Our results highlight the relevance of the SOX9-BMI1-p21 cip axis in tumor progression, shedding novel opportunities for therapeutic development.
breast or skin [19] [20] [21] [22] . Moreover, several studies have linked SOX9 to cancer initiation and the regulation of the population of cancer stem cells (CSCs) in multiples tissues 19, 21, 23 , promoting processes associated to this specific population such as metastasis or chemoresistance [24] [25] [26] [27] .
In clinical samples, SOX9 expression is elevated in glioblastoma, pancreatic ductal adenocarcinoma, gastric cancer, colon, skin or breast cancer samples respect to adjacent normal tissue [28] [29] [30] . Furthermore, high levels of SOX9 have been associated with tumor grade, dismal prognosis and poor patient survival in patients of those types of cancer 28, 31, 32 . Thus, SOX9 expression and function are altered in diverse human cancers, acting as an oncogene in a wide range of them, mainly through the regulation of CSCs activity, and as a tumor suppressor in specific situations 26 . Besides, it has been shown that Sox9 is able to promote proliferation and induce neoplastic transformation of primary fibroblasts 33 , indicative that SOX9 is relevant in cancer beyond its initiation and its role in CSC activity. In this regard, its activity in cells of tumor bulk and the underlying molecular mechanisms remain poorly understood. Therefore, in this study we elucidated the functional role of SOX9 in critical processes for cancer progression such as survival, proliferation and senescence in tumor differentiated cells, and deciphered its molecular mechanism, providing new knowledge regarding the role and molecular pathway of this critical stem cell factor on cancer progression and heterogeneity.
Results
SOX9 is required for tumor cell survival and proliferation. In order to assess the impact of SOX9 in tumor cell survival, we knocked down SOX9 expression in different cancer cell lines. In particular, we silenced SOX9 expression in cell lines of gastric cancer (AGS and MKN45), pancreatic cancer (Panc-1 and RWP-1) and glioblastoma (U373 and U251), which exhibit high SOX9 expression levels. After confirming the successful reduction of SOX9 levels in these cell lines ( Fig. 1A and Fig. Suppl) , we determined cell viability by cell count experiments. In these analyses, we observed a significantly reduced number of cells in SOX9-silenced cultures respect to control cells 5 days after the seeding (Fig. 1B) , indicating that SOX9 silencing compromises the viability of tumor cells.
In order to evaluate the role of SOX9 in cancer cell survival, we studied apoptosis. For this, we analyzed the activation of Caspase-3 and the proteolytic inactivation of PARP1 through immunofluorescence staining. These experiments revealed the presence of a significantly higher number of apoptotic cells in cultures with SOX9 silencing, with a marked increase of over 10 fold in both active Caspase-3 (Fig. 1C ,D) and cleaved PARP1-positive cells (Fig. 1E ,F) in SOX9-silenced cells respect to controls. Thus, SOX9 is required for cancer cell survival, wherein exerts an antiapoptotic role.
Given that cellular senescence constitutes a tumor-suppressive mechanism that restricts tumor progression, we explored whether SOX9 would mediate senescence evasion in cancer cells. To assess this aspect, we analyzed the senescence associated β-galactosidase activity in SOX9-silenced cells. We detected a significant increase in the number of β-galactosidase-positive cells in the different cancer types (Fig. 1G,H) , revealing that SOX9 silencing promotes the induction of senescence in cancer cells.
Next, we measured cell proliferation through the evaluation of the percentage of cells positive for the marker of mitosis phospho-Histone H3 (p-H3). Our results revealed a marked and significant decrease in mitotic cells in SOX9-silenced cancer cells respect to cells transduced with empty vector (Fig. 1I,J) . On the contrary, ectopic upregulation of SOX9 in cancer cell lines ( Fig. 2A ) resulted in a significant increase in the percentage of p-H3 positive cells in cultures from the 3 types of cancer ( Fig. 2B ), as well as increased cell count (Fig. 2C ). In line with this, tumors derived from MKN45 gastric cancer cells and U373 glioma cells with overexpression of SOX9 presented a markedly higher number of Ki67 positive cells than those tumors formed by control cells in vivo ( Fig. 2D ), together demonstrating that SOX9 regulates cancer cell proliferation. SOX9 expression regulates BMI1 and p21 cip levels. Next, we wanted to unravel the molecular mechanism underlying the role of SOX9 in cell survival and proliferation. Since we had previously found that Sox9 promotes proliferation and facilitates neoplastic transformation of primary fibroblasts via the transcriptional repressor Bmi1 33 , and other groups have shown that SOX9 induces cancer cell proliferation through downregulation of the tumor suppressor p21 CIP 34, 35 , we studied their expression.
We first investigated the effect of SOX9 silencing in their expression in the different tumor cell lines of various origins. Our results revealed that BMI1 protein expression was reduced in SOX9-silenced cells of PDAC, GBM and GC (Fig. 3A) , whereas p21 CIP levels were elevated (Fig. 3A ). Similar effect was also observed at transcriptional level ( Fig. 3B,C) . On the contrary, cells with ectopic SOX9 overexpression displayed elevated levels of BMI1 and lower p21 CIP expression ( Fig. 3D,E) . These results show that SOX9 regulates the expression of BMI1 and p21 CIP at transcriptional level in cancer cells in vitro and this might influence tumor cell survival and proliferation.
To further characterize the link between SOX9 expression with BMI1 and p21 CIP , we stained tumors derived from SOX9 silenced cells and controls with antibodies for BMI1 and p21 CIP , as well as for SOX9 and Ki67. Thus, confirming previous results revealing that SOX9 inhibition reduces tumor growth 25, 31 , immunohistochemistry analysis showed lower staining of SOX9 as well as reduction in Ki67 positive cells in gastric and pancreatic tumors with reduced SOX9 (Fig. 3F ). In these contexts, BMI1 staining was lower, whereas p21 CIP was increased in tumors derived from SOX9 knockdown cells (Fig. 3F ). These results show that SOX9 modulates the expression of BMI1 and p21 CIP in different cancer types in vivo.
Correlation between SOX9, BMI1 and p21 cip in clinical samples. Next, we wondered whether the association between SOX9, BMI1 and p21 CIP levels could be translated to clinical samples. Therefore, we checked the relationship between their expression using previously described cohorts 25 and available datasets from all genome-wide expression profiling arrays of glioblastoma, gastric and pancreatic cancer cohorts of patients. First, we found that SOX9 and BMI1 were increased by more than 5 and 2.5-fold respectively, while p21 CIP was not www.nature.com/scientificreports www.nature.com/scientificreports/ significantly altered in GBM compared to normal brain tissue ( Fig. 4A ). In line with this, 80% and 60% of the GBMs showed high levels of SOX9 and BMI1 respectively (fold change higher than 2 respect to normal brain), whereas 83% showed low or moderate expression of p21 CIP (Fig. 4B ). Moreover, majority of the biopsies with high SOX9 expression also presented increased levels of BMI1 and moderate or low p21 CIP levels ( Fig. 4C ).
Next, we checked the available information obtained by The Cancer Genome Atlas (TCGA) project and found a significant correlation between SOX9 and BMI1 in GBM ( Fig. 4D ), detecting also that the expression of SOX9 correlated positively with BMI1 expression and negatively with p21 CIP expression in gastric cancer ( Fig. 4D ). Finally, we analyzed the expression of these markers in 3 cohorts of gastric tumor-normal samples (n = 60), 2 of pancreatic tumor-normal samples (n = 124), and additional one of GBM and normal brain samples (n = 47). The comparison between normal and tumor tissue revealed frequent overexpression of SOX9 and BMI1, whereas p21 CIP levels were similar or decreased in tumor samples ( Fig. 4E ). Noteworthy, the heatmap representation revealed that the expression of SOX9 correlated positively with BMI1 expression and negatively with p21 CIP in samples from the different types of cancer ( Fig. 4F ). Similarly, there was an inverse correlation between SOX9 and p16 INK4a levels in the same samples ( Fig. 4F ). Importantly, these results translate the association of SOX9-BMI1-p21 CIP from tumor cells in vitro and in vivo tumors to clinical biopsies.
BMI1 restoration in SOX9-silenced cells rescues the malignant phenotype of tumor cells. The
fact that SOX9 modulation impacted on the expression of BMI1 in tumor cells in vitro and in vivo, suggested that BMI1 could constitute an effector of the pro-tumoral activity of SOX9. To further test this idea, we lentivirally transduced a construct encoding BMI1 gene in MKN45 GC cells and Panc-1 and RWP-1 pancreatic cancer cells with SOX9 knockdown or controls. The cells transduced with BMI1 encoding construct presented BMI1 overexpression in the case of control cells or restoration of BMI1 levels in SOX9 silenced cells (Fig. 5A) . Moreover, at www.nature.com/scientificreports www.nature.com/scientificreports/ molecular level, BMI1 restoration reduced the expression of p21 CIP respect to the levels found in SOX9-silenced cells (Fig. 5A) .
Then, we evaluated cellular phenotypes in terms of viability, apoptosis, proliferation and senescence in vitro. First, we noted that ectopic expression of BMI1 increased the number of tumor cells or restored the number counted in SOX9-silenced cultures (Fig. 5B) . Accordingly, ectopic BMI1 also abrogated significantly the induction of apoptosis promoted by SOX9 silencing, reducing by over 50% the percentage of cells with active Caspase-3 and proteolyzed PARP1 in gastric and pancreatic cancer cells (Fig. 5C,D) . Similarly, senescence induction by SOX9 silencing was significantly mitigated (over 50% reduction) by BMI1 restoration in tumor cells ( Fig. 5E ). Regarding cell proliferation, our results showed that BMI1 overexpression significantly increased the number of p-H3 positive cells compared to SOX9 knockdown cells (Fig. 5F ). This indicates that BMI1 re-establishes the proliferative capacity of cancer cells abrogated by SOX9 knockdown.
Finally, we tested whether BMI1 is necessary for SOX9 pro-tumoral activity in vivo. For this, we inoculated either control (pLKO) or SOX9-silenced (sh1) MKN45 or Panc-1 cells, which were also transduced with BMI1 or empty vector, to immunodeficient mice. While MKN45 control cell derived tumors grew to almost 200 mm 3 , those derived from sh1 cells only grew to 50 mm 3 (Fig. 6A,B) . Interestingly, BMI1 restoration completely abrogated the reduction of tumor growth elicited by SOX9 knockdown (Fig. 6A,B) . Similarly, BMI1 restoration also increased the tumor growth capacity of SOX9 knockdown Panc-1 cells (Fig. 6C) . Accordingly, immunohistochemistry of tumors derived from MKN45 cells showed increased number of Ki67 positive cells in sh1 with BMI1 restoration compared to sh1 alone (Fig. 6D ). Furthermore, this technique also revealed reduction in the staining of p21 CIP in tumors derived form cells with BMI1 restoration (Fig. 6D ). Overall, these results show that the ectopic restoration of BMI1 in SOX9-silenced cells recovers the aggressive phenotype of tumor cells.
Discussion
In this study, we show that SOX9 plays a role in cancer progression, not only regulating the activity of CSCs, but also modulating the function of the heterogeneous tumor cells that constitute the tumor bulk. In this context, SOX9 affects a broad plethora of cellular processes that contribute to tumor progression. In particular, SOX9 maintains cell viability, is relevant for cell survival and senescence evasion and promotes proliferation. At the mechanistic level, the transcriptional repressor BMI1 is an important effector of SOX9 in those processes through the negative regulation of p21 CIP .
We found that SOX9 activity impacts on cell viability and influences cell proliferation in differentiated pancreatic, glioblastoma and gastric cancer cells. Furthermore, our data reveal that SOX9 silencing promotes that tumor cells undergo senescence and apoptosis. In agreement with our findings, it has been previously observed that high levels of Sox9 were sufficient to bypass cellular senescence 33 and prevented apoptosis in non-tumor cells 36 . Our results highlight the function of SOX9 in controlling multiple processes associated to cancer and, hence explaining, how SOX9 potentiates tumor progression not only regulating the activity of CSCs.
BMI1 is an important epigenetic regulator, which restricts cell proliferation and mediates senescence and apoptosis during homeostasis 37 . In cancer, its levels are commonly elevated and it plays a potent oncogenic role in multiple types of cancer including pancreatic, glioblastoma and gastric cancer [38] [39] [40] . In this work, we found that modulation of SOX9 levels affects BMI1 expression in multiple cancer cell lines in vitro and in vivo. These results are in agreement with previous studies that linked SOX9 and BMI1 in primary fibroblasts and colorectal CSCs 23, 33 . This regulation is likely to be direct since chromatin immunoprecipitation experiments have shown that SOX9 binds to the promoter of BMI1 in different types of cells and contexts 33, 41 . Moreover, our results show that there is also a positive correlation between SOX9 and BMI1 expression, and negative between SOX9 and p21 CIP in clinical samples. In line with this, previous studies analyzed the correlation between SOX9, BMI1 and p21 CIP in different types of cancers and showed independently that SOX9 regulates proliferation through a positive correlation with BMI1 and an inverse correlation with p21 CIP expression 23, 31, [33] [34] [35] . Together, these results highlight that BMI1 is a relevant mediator of SOX9 in promoting tumor malignancy and show the importance of this axis in cancer progression, thus providing new therapeutic possibilities, such as BMI1 inhibition, a strategy that is being currently evaluated in different cancer clinical trials. Thus, the trial NCT03761095 is aimed at evaluating the safety of the orally active BMI1 inhibitor PTC596 (PTC Therapeutics) in combination with dacarbazine for the treatment of advanced leiomyosarcoma. Moreover, also the trials NCT03206645 and NCT03605550 are currently evaluating this inhibitor. The first is a dose-escalation study oriented to evaluate its safety, tolerability and pharmacokinetics in combination with conventional chemotherapy for the treatment of ovarian and fallopian tube cancer or primary peritoneal cancer. The latter tries to determine the safe dose of PTC596 for its administration in combination with radiation in children with newly diagnosed diffuse intrinsic pontine glioma and high-grade glioma.
BMI1 represses the transcription of multiple genes including relevant tumor suppressor genes such as p21 , as well as the Ink4a/Arf locus, encoding p14 Arf and p16 INK4a , being the latter the best-known target between SOX9 and p21 CIP mRNA expression (Spearman's correlation = −0.123, p-value = 0.0478, n = 258). Data obtained from https://www.cancer.gov/tcga. (E) Violin plots representing the expression of SOX9, BMI1 and p21 CIP analyzed by microarrays in normal (N) and tumor (T) samples of three gastric cancer cohorts (datasets GSE13911, GSE79973 and GSE19826), two pancreatic adenocarcinoma cohorts (datasets GSE16515 and GSE15471) and one GBM cohort (dataset GSE50161). The black dots represent the individual expression values and the symbol + denote the mean values of the distributions. (F) Heatmap representing the expression of SOX9, BMI1, p21 CIP (CDKN1A) and p16 Ink4a (CDKN2A) in normal and tumor tissue samples belonging to the datasets represented in (E).
Scientific RepoRtS |
(2020) 10:357 | https://doi.org/10.1038/s41598-019-57047-w www.nature.com/scientificreports www.nature.com/scientificreports/ in cell growth arrest and senescence 37 . Indeed, we have previously shown that Sox9 promotes proliferation and favors neoplastic transformation of primary cells through Bmi1, whose upregulation consequently represses the expression of Ink4a and Arf genes 33 . Ink4a/Arf locus is frequently mutated and inactivated in human cancers 45 , as it is the case also of many tumor cell lines including the ones used in this study. Thus, the action of SOX9-BMI1 www.nature.com/scientificreports www.nature.com/scientificreports/ axis in driving processes associated to tumor progression is not attributable to the repression of p16 INK4a and/or p14 Arf . Indeed, our results show that this axis promotes tumor cell survival and proliferation via p21 CIP , since the restoration of BMI1 levels in SOX9 silenced cells, also modulated, in this case inhibited, the expression of this tumor suppressor. Thus, we postulate that the axis SOX9-BMI1 plays a relevant role in the different stages of cancer initiation and progression, in which they inhibit the expression of tumor suppressors sequentially. The repression of Ink4a/Arf locus is required at early stages of neoplastic transformation and tumor formation, whereas the repression of p21 CIP is necessary in the action exerted by the axis SOX9-BMI1 for cancer progression (Fig. 7) .
In summary, our findings show that SOX9 is highly relevant in the survival of population of cells constituting the tumor bulk in multiple types of cancer contributing to evasion of apoptosis. Moreover, we reveal that SOX9 controls the proliferative capacity of tumor cells and facilitates evading senescence. Mechanistically, SOX9 exerts these pro-tumoral actions through BMI1-p21 CIP , providing novel knowledge regarding the molecular events leading to cancer progression.
Experimental Procedures
Human subjects. Clinical information of glioblastoma patients was obtained from the Donostia University Hospital. Human glioma samples were provided by the Basque Biobank for Research-OEHUN (http://www. biobancovasco.org). All study participants signed informed consent form approved by the Institutional Ethical Committee. The study was approved by the ethic committee of Euskadi (PI2016151). All methods were performed in accordance with the relevant guidelines and regulations. Western blot. Immunoblots were performed following standard procedures. Primary antibodies used were: SOX9 (AB5535, Millipore), BMI1 (05-637, Millipore), p21 CIP (sc-397-G, Santa Cruz Biotechnology), GFP (ab6673, abcam) and β-actin (AC-15, Sigma). Primary antibodies were detected with HRP-linked secondary antibodies: anti-rabbit (7074S, Cell Signaling Technology), anti-mouse (7076S, Cell Signaling Technology) and anti-goat (sc-2020, Santa Cruz Biotechnology). Protein bands were detected using the ECL system (NOVEX ® ECL, Invitrogen).
Immunofluorescence. For immunofluorescent detections, cells were seeded in Lab-Tek II Chamber Slides (ThermoFisher Scientific) and fixed with 4% paraformaldehyde for 15 min at RT. Then, cells were incubated with PBS supplemented with 0.3% Triton X-100 and 5% FBS for 1 hour at RT. Cells were incubated overnight at 4 °C with different primary antibodies: phospho-histone H3 (phospho S10) (ab14955, Abcam), Cleaved PARP1 (ab32064, Abcam) and Active Caspase 3 (AF835, R&D Systems). Secondary antibodies conjugated to fluorochromes were incubated for 1 hour at RT and chromatin staining was performed with Hoechst 33342 (Molecular Probes). Slides were mounted with Fluoro-Gel mounting medium (Electron Microscopy Sciences) and preparations were visualized and documented using a Nikon Eclipse 80i microscope. β-Galactosidase activity. To analyze cellular senescence, β-Galactosidase activity was measured in cells using the Senescence β-Galactosidase Staining Kit of Cell Signaling Technology (#9860), according to the manufacturer's protocol. Briefly, cells were fixed and incubated overnight at 37 °C in a dry incubator with a staining solution containing X-Gal. Cells were observed in an inverted light microscope and different views were captured randomly to calculate the positive staining rate for each experimental condition. mRNA expression analysis. Total RNA was extracted with trizol (Life Technologies). Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher) according to the manufacturer's guidelines. Quantitative real-time PCR was performed in an ABI PRISM 7300 thermocycler Figure 7 . Pro-tumoral action and molecular mechanism of SOX9 in cancer. In the context of non-tumor cells (left panel), SOX9 is able to promote neoplastic transformation through the induction of cell proliferation and the evasion of senescence. At the molecular level, this transformation takes place through the induction of BMI1 expression, which represses the expression of the tumor suppressors p16 INK4A and ARF (previously described by Matheu et al., 2012) . In the context of tumor cells (right panel), generally deficient in p16 INK4A and ARF expression, SOX9 enhances tumor progression through the promotion of cell proliferation and the evasion of apoptosis and senescence. In this context, the molecular mechanism involves the repression of the tumor suppressor p21 CIP .
In vivo carcinogenesis assays. All animal handling and protocols were approved by the animal care ethic committee of Biodonostia Institute and were conducted in conformity with the EU guidelines and regulations for animal experimentation. For subcutaneous injection, cells were harvested with trypsin/EDTA and resuspended in PBS. 1 × 10 5 MKN45 cells and 0.5 × 10 6 Panc-1 cells were injected into both flanks of 8 week-old Foxn1 nu / Foxn1 nu mice. External calipers were used to measure tumor size, from which tumor volume was estimated by V = L*W 2 *0.5, where L is the tumor length and W is the tumor width.
Hematoxylin and eosin staining and immunohistochemistry. Tumors generated in mice were dissected, fixed in 10% formalin for 48 hours and embedded in paraffin. 4 µm thick sections were stained with hematoxylin and eosin (H&E). For immunohistochemistry, sections were rehydrated and heated in citrate buffer pH 6 for antigen retrieval. Antibodies used for detections included SOX9 (AB5535, Millipore), BMI1 (05-637, Millipore), p21 CIP (sc-6246, Santa Cruz Biotechnology) and Ki67 (ab15580, Abcam). The stainings were developed with 3,3′ Diaminobenzidine (DAB) and nuclei were counterstained with hematoxylin.
Data evaluation. Data are presented as mean values ± standard error (SEM), with the number of experiments (n) in parentheses. Unless otherwise indicated, statistical significance (p-values) was calculated using the Student´s t -test. Asterisks (*, ** and ***) indicate statistical significance (p < 0.05, p < 0.01, and p < 0.001, respectively).
